

# Employee Post-Travel Disclosure of Travel Expenses

Date/Time Stamp:

RECEIVED  
SECRETARY OF THE SENATE  
PUBLIC RECORDS

2019 SEP 18 PM 3:56

**Post-Travel Filing Instructions:** Complete this form within 30 days of returning from travel. Submit all forms to the **Office of Public Records in 232 Hart Building.**

In compliance with Rule 35.2(a) and (c), I make the following disclosures with respect to travel expenses that have been or will be reimbursed/paid for me. I also certify that I have attached:

☒ The **original** *Employee Pre-Travel Authorization* (Form RE-1), **AND**

☒ A **copy** of the *Private Sponsor Travel Certification Form* with all attachments (itinerary, invitee list, etc.)

Private Sponsor(s) (list all): PATH/Global Health Technologies Coalition (GHTC) & International AIDS Vaccine Initiative (IAVI)

Travel date(s): August 17 - 24, 2019

Name of accompanying family member (if any): \_\_\_\_\_

Relationship to Traveler: ☐ Spouse ☐ Child

IF THE COST OF LODGING DID NOT INCREASE DUE TO THE ACCOMPANYING SPOUSE OR DEPENDENT CHILD, ONLY INCLUDE LODGING COSTS IN EMPLOYEE EXPENSES. (Attach additional pages if necessary.)

## Expenses for Employee:

	Transportation Expenses	Lodging Expenses	Meal Expenses	Other Expenses (Amount & Description)
<input type="checkbox"/> Good Faith Estimate <input checked="" type="checkbox"/> Actual Amount	\$2,372.17	\$942.04	\$139.23 (good faith estimate - two catered meal costs estimated)	\$51.50 (Ugandan visa application cost)

## Expenses for Accompanying Spouse or Dependent Child (if applicable):

	Transportation Expenses	Lodging Expenses	Meal Expenses	Other Expenses (Amount & Description)
<input type="checkbox"/> Good Faith Estimate <input type="checkbox"/> Actual Amount				

Provide a description of all meetings and events attended. See Senate Rule 35.2(c)(6). (Attach additional pages if necessary.):

See attached itinerary for full description of all meetings and events attended

9/18/19  
(Date)

Jacob Vance  
(Printed name of traveler)

Jacob C. Vance  
(Signature of traveler)

## TO BE COMPLETED BY SUPERVISING MEMBER/OFFICER:

I have made a determination that the expenses set out above in connections with travel described in the *Employee Pre-Travel Authorization* form, are necessary transportation, lodging, and related expenses as defined in Rule 35.

9/18/2019  
(Date)

Jerry Moran

(Signature of Supervising Senator/Officer)



July 2, 2019

Dear Jacob:

PATH/Global Health Technologies Coalition (GHTC) and International AIDS Vaccine Initiative (IAVI) are pleased to invite you on a unique learning trip to Uganda, where you will have the opportunity to see firsthand how US investments are working to address key global health challenges through transformative investments in research and development (R&D). The trip will take place from August 17–24, 2019 (including travel days) and will include meetings with US, Ugandan, and NGO partners; visits to research, clinical, and program sites in the field; and interactions with health workers and community members. We hope this trip will be a resource for your office as you consider the US government's role in improving global health, in particular through investments in R&D for new tools like drugs, vaccines, and diagnostics for use in low-resource settings.

Uganda is a hub for cutting-edge scientific research and is a critical partner of the United States on shared global health research objectives. Long-standing partnerships between universities in the United States and Uganda have produced life-saving global health tools and trained a new generation of researchers and clinicians, building the capacity of Uganda and other countries in the region to discover solutions to their most pressing health challenges. Clinical research sites in Uganda have hosted trials that have resulted in new drugs, vaccines, and diagnostics for disease threats that affect populations in both countries, such as HIV/AIDS, and informed global treatment and prevention guidelines. Continued scientific partnership, nourished by US investments through the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), US Agency for International Development (USAID), Department of Defense, and other agencies, is critical to advance progress against long-standing health threats and prepare for the unknown pathogens of the future.

We will start our trip in the capital city of Kampala, home to some of the preeminent universities and research institutes in Africa. Meetings with key US and Ugandan officials will set the stage for visits to sites including the Makerere University–Johns Hopkins University Research Collaboration at Mulago Hospital focused on HIV prevention, the Uganda–Case Western Reserve University Research Collaboration Tuberculosis Project Clinic, and the Infectious Diseases Institute at Makerere University, where research supported by NIH, CDC, and international partners is advancing new products and approaches to combat HIV/AIDS, TB, meningitis, cervical cancer, and other infectious diseases.

After transiting to nearby Entebbe, we will tour the Uganda Virus Research Institute (UVRI), a international scientific hub known for the discovery of viruses including Zika, West Nile, and Chikungunya, pioneering research in HIV/AIDS, and its capacity as an international reference laboratory. Site visits to see neighboring communities, including some on remote islands on Lake Victoria, will showcase how clinical trials supported by the US government enroll participants to test new health products and interventions, improving health locally and driving global health progress. A tour of the UVRI protected field research station in the Zika Forest—known for the discovery of the virus of the same name—will showcase how research on site has contributed to the understanding of and response to mosquito-borne viruses around the globe. Throughout the week, trip participants will also gain a better understanding of Uganda's leadership in global health security, and how US investments have contributed to the country's preparedness for the potential spread of Ebola from the neighboring Democratic Republic of the Congo.

We hope to have the opportunity to spend a transformative week with you in Uganda seeing the life-saving impact of US global health R&D activities.

Sincerely,

Emily Conron  
US Policy and Advocacy Officer  
Global Health Technologies Coalition

Jenni Maple  
Advocacy Manager  
International AIDS Vaccine Initiative

*The Global Health Technologies Coalition (GHTC) Secretariat, housed at PATH, is a group of more over 30 nonprofit organizations, academic institutions, and aligned businesses advancing policies to accelerate the creation of new drugs, vaccines, diagnostics, and other tools that bring healthy lives within reach for all people.*

*The International AIDS Vaccine Initiative (IAVI) is a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges including HIV and tuberculosis. Our mission is to translate scientific discoveries into affordable, accessible public health solutions for the people who need them most.*



## PRIVATE SPONSOR TRAVEL CERTIFICATION FORM

This form must be completed by any private entity offering to provide travel or reimbursement for travel to Senate Members, officers, or employees (Senate Rule 35, clause 2). Each sponsor of a fact-finding trip must sign the completed form. The trip sponsor(s) must provide a copy of the completed form to each invited Senate traveler, who will then forward it to the Ethics Committee with any other required materials. The trip sponsor(s) should **NOT** submit the form directly to the Ethics Committee. Please consult the accompanying instructions for more detailed definitions and other key information.

The Senate Member, officer, or employee **MUST** also provide a copy of this form, along with the appropriate travel authorization and reimbursement form, to the Office of Public Records (OPR), Room 232 of the Hart Building, within thirty (30) days after the travel is completed.

1. Sponsor(s) of the trip (please list all sponsors): PATH / Global Health Technologies Coalition (GHTC)\* & International AIDS Vaccine Initiative (IAVI) (\*see Addendum for explanation of PATH/GHTC)
2. Description of the trip: This trip is an opportunity to see how firsthand how US investments in research and development (R&D) in Uganda are making an impact on key global health challenges.
3. Dates of travel: August 17 - 24, 2019
4. Place of travel: Kampala and Entebbe, Uganda
5. Name and title of Senate invitees: see Addendum
6. I *certify* that the trip fits one of the following categories:  
☐ (A) The sponsor(s) are not registered lobbyists or agents of a foreign principal **and** do not retain or employ registered lobbyists or agents of a foreign principal **and** no lobbyist or agents of a foreign principal will accompany the Member, officer, or employee *at any point* throughout the trip.  
**=OR=**  
☒ (B) The sponsor or sponsors are not registered lobbyists or agents of a foreign principal, but retain or employ one or more registered lobbyists or agents of a foreign principal and the trip meets the requirements of Senate Rule 35.2(a)(2)(A)(i) or (ii) (*see question 9*).
7. ☒ I *certify* that the trip will not be financed in any part by a registered lobbyist or agent of a foreign principal.  
**=AND=**  
☒ I *certify* that the sponsor or sponsors will not accept funds or in-kind contributions earmarked directly or indirectly for the purpose of financing this specific trip from a registered lobbyist or agent of a foreign principal or from a private entity that retains or employs one or more registered lobbyists or agents of a foreign principal.
8. I *certify* that:  
☒ The trip will not in any part be planned, organized, requested, or arranged by a registered lobbyist or agent of a foreign principal except for *de minimis* lobbyist involvement.  
**=AND=**  
☒ The traveler will not be accompanied on the trip by a registered lobbyist or agent of a foreign principal except as provided for by Committee regulations relating to lobbyist accompaniment (*see question 9*).

9. **USE ONLY IF YOU CHECKED QUESTION 6(B)**

I *certify* that if the sponsor or sponsors retain or employ one or more registered lobbyists or agents of a foreign principal, one of the following scenarios applies:

☐ (A) The trip is for attendance or participation in a one-day event (exclusive of travel time and one overnight stay) and no registered lobbyists or agents of a foreign principal will accompany the Member, officer, or employee *on any segment* of the trip.

**OR**

☐ (B) The trip is for attendance or participation in a one-day event (exclusive of travel time and two overnight stays) and no registered lobbyists or agents of a foreign principal will accompany the Member, officer, or employee *on any segment* of the trip (see questions 6 and 10).

**OR**

☒ (C) The trip is being sponsored only by an organization or organizations designated under § 501(c)(3) of the Internal Revenue Code of 1986 and no registered lobbyists or agents of a foreign principal will accompany the Member, officer, or employee *at any point* throughout the trip.

10. **USE ONLY IF YOU CHECKED QUESTION 9(B)**

If the trip includes two overnight stays, please explain why the second night is practically required for Senate invitees to participate in the travel:

(N/A)

11. ☒ An itinerary for the trip is attached to this form. I *certify* that the attached itinerary is a detailed (hour-by-hour), complete, and final itinerary for the trip.

12. Briefly describe the role of each sponsor in organizing and conducting the trip:

PATH/GHTC & IAVI jointly identified Senate invitees, issued invitations, liaised with Ugandan partners to identify and select site visits for the itinerary, and arranged travel and accommodations. IAVI, through their team in Uganda, is leading logistical arrangements in country, splitting costs...(see Addendum)

13. Briefly describe the stated mission of each sponsor and how the purpose of the trip relates to that mission:

PATH/GHTC is a group of over 30 nonprofit organizations, academic institutions, and aligned businesses advancing policies to accelerate the creation of new drugs, vaccines, diagnostics, and other global health tools. IAVI is a nonprofit (501c3) scientific research organization dedicated to...(see Addendum)

14. Briefly describe each sponsor's prior history of sponsoring congressional trips:

PATH/GHTC, with several partners, sponsored a congressional staff learning trip to the CDC campus in Atlanta in August 2018. PATH/GHTC also served as one of several co-sponsors of a trip to South Africa in 2016 to educate staffers about tuberculosis. IAVI has not previously sponsored a congressional trip.

15. Briefly describe the educational activities performed by each sponsor (other than sponsoring congressional trips):

Both PATH/GHTC & IAVI produce reports and briefing materials on the impact of US investment in global health R&D, meet with congressional and agency representatives to discuss US support of global health R&D, and raise awareness of the importance of R&D to eliminating diseases globally.

16. Total Expenses for Each Participant:

	Transportation Expenses	Lodging Expenses	Meal Expenses	Other Expenses
<input checked="" type="checkbox"/> Good Faith estimate	\$2,800 (see Addendum for more details)	\$1,028 (see Addendum for more details)	\$385 (see Addendum for more details)	\$51.50 (see Addendum for more details)
<input type="checkbox"/> Actual Amounts				

17. State whether a) the trip involves an event that is arranged or organized *without regard* to congressional participation or b) the trip involves an event that is arranged or organized *specifically with regard* to congressional participation:

B) The trip involves an event that is arranged or organized specifically with regard to congressional participation.

18. Reason for selecting the location of the event or trip

Uganda is a key strategic partner for the US on a range of health and development goals and receives more than \$430 million in assistance annually, including R&D funding through NIH, CDC, USAID & DoD.

19. Name and location of hotel or other lodging facility:

Protea Hotel by Marriott Kampala, Elgon Terrace, 9421, John Babiha (Acacia) Avenue, Kampala

Protea Hotel by Marriott Entebbe, 36-40 Sebugwawo Drive, Entebbe Road, Entebbe

20. Reason(s) for selecting hotel or other lodging facility:

Both hotels satisfy security requirements and are centrally located to site visits and meeting locations.

The Protea Kampala is centrally located to the Ugandan Ministry of Health and site visits, while the Protea

Entebbe is situated close to the Uganda Virus Research Institute, often hosting visitors to the site.



21. Describe how the daily expenses for lodging, meals, and other expenses provided to trip participants compares to the maximum per diem rates for official Federal Government travel:

The daily expense for lodging, meals and other expenses are below the maximum per diem for the days in Kampala but slightly over for the days in Entebbe. The daily expenses for lodging, meals, and other expenses are, in total, below the maximum per diem rates for official Federal...(see Addendum)

22. Describe the type and class of transportation being provided. Indicate whether coach, business-class or first class transportation will be provided. If first-class fare is being provided, please explain why first-class travel is necessary:

Round-trip coach air transportation; ground transportation in a locally-arranged van; transportation via IAVI-owned boat to island communities on Lake Victoria (fuel cost to be reimbursed)

23. ☒ I represent that the travel expenses that will be paid for or reimbursed to Senate invitees do not include expenditures for recreational activities, alcohol, or entertainment (other than entertainment provided to all attendees as an integral part of the event, as permissible under Senate Rule 35).

24. List any entertainment that will be provided to, paid for, or reimbursed to Senate invitees and explain why the entertainment is an integral part of the event:

None

25. I hereby *certify* that the information contained herein is true, complete and correct. (For trips involving more than one sponsor, you *must* include a completed signature page for each additional sponsor):

Signature of Travel Sponsor: Emily Conron

Name and Title: Emily Conron, US Policy and Advocacy Officer, Global Health Technologies Coalition

Name of Organization: PATH

Address: 455 Massachusetts Ave. NW, Suite 1000

Telephone Number: 202.540.4403

Fax Number: 202.457.1466


E-mail Address: econron@ghtcoalition.org

**PRIVATE SPONSOR TRAVEL CERTIFICATION FORM**

**SIGNATURE PAGE FOR ADDITIONAL SPONSOR**

*(to be completed by each additional sponsor)*

I hereby *certify* that the information contained on pages 1-4 of the certification form and any accompanying addenda, all submitted in connection with the August 17 - 24, 2019 trip  
to Uganda *Place of Travel* is true, complete, and correct. *Dates of Travel (Month Day, Year)*

Signature of Travel Sponsor: 

Name and Title: Jennifer Maple, Advocacy Manager

Name of Organization: International AIDS Vaccine Initiative (IAVI)

Address: 125 Broad Street, 9th Floor

Telephone Number: 212-847-1084

Fax Number: 212-847-1113

E-mail Address: jmaple@iavi.org

000000005242

**M  
ST  
LN  
CO  
CO  
CO  
CO  
CO  
CO  
CO**

**M  
ST  
LN  
CO  
CO  
CO  
CO  
CO  
CO  
CO**

MS  
ST  
LN  
CP  
CP  
CP  
CP  
CP  
CP  
CP  
CP  
CP

MS  
ST  
LN  
CP  
CP  
CP  
CP  
CP  
CP  
CP  
CP  
CP

- MS  
ST  
LN  
CP  
CP  
CP  
CP  
CP  
CP  
CP  
CP  
CP

MS  
ST  
LN  
CP  
CP  
CP  
CP  
CP  
CP  
CP  
CP  
CP

- MS  
ST  
LN  
CP  
CP  
CP  
CP  
CP  
CP  
CP  
CP  
CP

MS  
ST  
LN  
CP  
CP  
CP  
CP  
CP  
CP  
CP  
CP  
CP

- MS  
ST  
LN  
CP  
CP  
CP  
CP  
CP  
CP  
CP  
CP  
CP





11. Complete and final itinerary – separate document

21. Describe how the daily expenses for lodging, meals, and other expenses provided to trip participants compares to the maximum per diem rates for official Federal Government travel:

- ...Government travel in Kampala and Entebbe combined.

Detailed breakdown of costs (good faith estimates) compared to per diem rates:

Transportation Expenses	Lodging Expenses	Meal Expenses	Other Expenses
<b>\$2,800</b> Flight (coach, roundtrip): \$2,500 Van: \$250 Boat (fuel reimbursement to partner): \$50	<b>\$1,028</b> (5 nights hotel)	<b>\$385</b>	<b>\$51.50</b> Visa fee: \$51.50

Day	City	State Department Maximum Per Diem Rate (hotels)	State Department Maximum Per Diem Rate (M&E)	Hotel (incl. breakfast)	Meals
1	Kampala	\$250	\$90	\$214	\$77
2	Kampala	\$250	\$90	\$214	\$77
3	Entebbe	\$172	\$73	\$200*	\$77*
4	Entebbe	\$172	\$73	\$200*	\$77*
5	Entebbe	\$172	\$73	\$200*	\$77*
	Total:	\$1,016	\$399	\$1,028	\$385
		TOTAL: \$1,415		TOTAL: \$1,413	

\*Note: The hotel in Entebbe is \$28 over the maximum per diem rate and the Entebbe M&E is above the maximum per diem rate by \$4 but the total expenses of the entire trip fall below the maximum per diem rates for official Federal Government travel in Kampala and Entebbe combined. The reason for the increased costs in Entebbe for both lodging and M&E is to ensure security requirements are met for the participants during their time outside of the capital city. This includes staying at a hotel with the necessary level of security and providing the majority of meals at the hotel to minimize the movement of participants in Entebbe at night.

**August 17 – 24, 2019**

5:35 pm Depart Washington, D.C. from Dulles to Entebbe (via Brussels) on United Airlines

**10:15 pm**                      **Arrival in Entebbe**

11:00 pm	Transit to hotel in Kampala and check in
----------	--

**Overnight: Protea Hotel by Marriott Kampala**

**Location:** Kampala

**Attire: Business**

8:30–9:00 am	Breakfast and daily briefing reviewing daily itinerary and introducing points for discussion during site visits
--------------	---

**Location:** Protea Hotel by Marriott Kampala

**9:00–10:00 am** Welcome and orientation from GHTC and IAVI staff

**Location:** Protea Hotel by Marriott Kampala

10:00–10:30 am	Transit to US Embassy and proceed through security
----------------	--

10:30–11:00 am	Courtesy call and introduction to US Mission to Kampala from US Ambassador to Uganda, <b>Deborah Malac</b> . Brief presentation to convey how Uganda is a key strategic partner for the US and how US foreign assistance promotes good governance, human rights, and multi-party democracy and addresses key health threats, including HIV/AIDS, emerging infectious diseases, and malaria, including through R&D efforts.
----------------	--

**Location:** US Embassy, Kampala

11:00 am–12:00 pm	Meeting with US Mission country team, including <b>Amb. Malac; Colette Marcellin</b> , Deputy Chief of Mission; <b>Dr. Lisa Nelson</b> , Centers for Disease Control and Prevention (CDC) Mission Director; and invited representatives from the President's Emergency Plan for AIDS Relief (PEPFAR), United States Agency for International Development (USAID), National Institutes of Health (NIH), Walter
-------------------	---



Reed Army Institute of Research (WRAIR), and the Peace Corps. High-level discussion on US government (USG) investments, strategies, and priorities in Uganda.

12:00–1:00 pm

Lunch – brown bag pre-ordered from Embassy on-site restaurant  
*Location:* US Embassy, Kampala

1:00–1:30 pm

Briefing on USG-supported research and development (R&D) in Uganda from Interagency Health Team, with representatives from CDC, PEPFAR, USAID, NIH, and WRAIR giving an overview of each agency's unique contribution to global health R&D. Discussion will focus on US government investments, strategies, and priorities in Uganda with regard to R&D, with the goal of giving trip participants an improved understanding of the USG role in partnership with Ugandan researchers. This discussion will help set the stage for site visits and give context to the work that will be seen over the course of the trip.  
*Location:* US Embassy, Kampala

1:30–2:15 pm

Transit to Public Health Emergency Operations Center adjacent to Ugandan Ministry of Health

2:15–3:15 pm

Tour Public Health Emergency Operations Center (EOC) accompanied by leadership staff and CDC Center for Global Health staff seconded to site. Showcase how the establishment of the EOC, as one of the three major pillars of the CDC Global Health Security Demonstration Project in Uganda, has strengthened political and technical linkages between CDC Uganda and the Ugandan Ministry of Health, and has been leveraged to respond to more than 70 outbreaks and public health events. Highlight how USG investments in products for Ebola preparedness and response are being deployed to strengthen global health security and prevent the further spread of the Ebola epidemic in neighboring Democratic Republic of the Congo, and how these investments are part of USG's commitment to the Global Health Security Agenda.  
*Location:* Public Health Emergency Operations Center

3:15–3:45 pm

Transit to Ugandan Ministry of Health and proceed through security

3:45–4:45 pm

Courtesy call with Ugandan Ministry of Health (MoH) officials, including Permanent Secretary of the Ministry of Health, **Dr. Diana Atwiine**. Briefing on major health issues facing Uganda and how US-Uganda partnerships on health programs and R&D efforts are making progress. Discussion will touch on both the challenges and opportunities to improve health outcomes in Uganda and the region through R&D. Meeting will help grow participants' understanding of

the role of the MoH and how it works in collaboration with USG on shared priorities.

*Location:* Ugandan Ministry of Health

4:45–6:00 pm

Transit to evening reception

6:00–7:30 pm

Evening reception with US Chief of Mission. Discussion of the US partnership with Uganda and areas of focus for future collaboration, with an emphasis on opportunities in R&D.

*Location:* US Chief of Mission residence

7:30 pm

Transit to hotel, optional dinner onsite

Overnight: Protea Hotel by Marriott Kampala

## Day 2 – Tuesday, August 20

*Location:* Kampala

*Attire:* Business casual

8:00–8:30 am

Check out of hotel and store bags for evening pick-up

8:30–9:30 am

Breakfast and daily briefing reviewing daily itinerary and introducing points for discussion during site visits

*Location:* Protea Hotel by Marriott Kampala

9:30–10:15 am

Transit to Makerere University–Johns Hopkins University Research Collaboration site at Mulago Hospital complex

10:15–11:30 am

Tour of Makerere University–Johns Hopkins University Research Collaboration (MUJHU) site at Mulago Hospital complex. **Dr. Phillipa Musoke**, Site Leader and Principal Investigator for Makerere University, and **Dr. Monica Nolan**, Deputy Director and Site Representative for Johns Hopkins University, will give a short presentation on MUJHU's ground-breaking research on HIV prevention methods for women and the prevention of mother-to-child HIV transmission, emphasizing how USG R&D funding is contributing to the achievement of the elimination of mother to child HIV transmission and promising new research to break the cycle of HIV transmission. The presentation will highlight pivotal studies conducted at the site which have contributed to the development of new tools to prevent HIV/AIDS and informed global guidelines and policies. Over 10,000 women have been enrolled in perinatal HIV prevention trials at MUJHU, including the landmark HIVNET 012 (single dose Nevirapine for mother and baby), HPTN 046 (extended infant NVP prophylaxis during breastfeeding), and

**Walk to Uganda—Case Western Reserve University Research Collaboration TB Project Clinic (on Mualgo Hospital complex)**





vaccines and TB and antiretroviral therapy; studies of the immunology of TB infection and progression from TB infection to active TB; TB and HIV interactions; TB diagnostics; and the evaluation of new microbial and immunologic biomarkers of response to TB treatment to expedite testing of new TB drugs, drug combinations and vaccines.

**Location:** Mualgo Hospital complex

2:30–3:15 pm

### Transit to Makerere University Main Campus

3:15–3:25 pm

Briefing by **Dr. Andrew Kambugu**, the Sande-McKinnell Executive Director of the Infectious Diseases Institute (IDI), College of Health Sciences, Makerere University. Dr. Kambugu will give a high-level overview of IDI research supported by NIH, CDC, and international partners that is advancing new products and approaches to combat HIV/AIDS, TB, meningitis, cervical cancer, and other infectious diseases.

**Location:** Makerere University Main Campus

3:25–3:40 pm

**Overview of NIH Intramural Program in Uganda by Victor Ssempijja, Biostatistician with the Clinical Monitoring Research Program Directorate.**

3:40–4:30 pm

Short overviews of project-specific research highlights, including poster presentations on key global health research findings supported by IDI, led by Dr. **Barbara Castelnovo**, Head of Research, IDI.

4:30–5:00 pm

Tour of the Bioinformatics and Big Data Centre, led by Dr. Daudi Jjingo, Program Director/Principal Investigator for the Ugandan NIH H3Africa bioinformatics training program. Makerere University, in partnership with the NIH National Institute of Allergy and Infectious Diseases and the Office of Cyber Infrastructure and Computational Biology, launched the African Centre of Excellence (ACE) in Bioinformatics and Data Intensive Sciences in March. The first facility of its kind in the region, the ACE serves as a center for computational biology and big data analysis and supports graduate and post-graduate training in bioinformatics, R&D support, human and pathogen DNA sequencing, biostatistics and image processing, and virtual reality (VR) infrastructure and services. The tour will highlight the state-of-the-art VR, tele-learning, and high-performance computing facilities.

**Location:** IDI McKinnell Centre, Makerere University Main Campus

5:00–5:45 pm

### Transit to dinner

5:45–7:00 pm

Dinner with early-career investigators based at IDI and Dr. Kambugu to learn more about their specific research areas and the impact of USG support for research and training in infectious diseases.

*Location:* Cantine Divino Restaurant

7:00–7:30 pm

Transit to hotel; pick up bags

*Location:* Protea Hotel by Marriott Kampala

7:30–8:30 pm

Transit to Entebbe

8:30 pm

Check in to Entebbe hotel

Overnight: Protea Hotel Entebbe

### Day 3 – Wednesday, August 21

*Location:* Entebbe

*Attire:* Business casual

7:30–8:30 am

Breakfast and daily briefing reviewing daily itinerary and introducing points for discussion during site visits

8:30–9:00 am

Transit to Uganda Virus Research Institute (UVRI) campus

9:00–10:00 am

Meet with **Professor Pontiano Kaleebu**, Director of UVRI, and senior UVRI staff. Participants will gain a holistic understanding of UVRI's research impact, hear about UVRI's mission/mandate and structure, appreciate the facility's long history and contributions to combatting infectious diseases, and learn about the Institute's programmatic activities and research capacities.

The Uganda Virus Research Institute (UVRI) is a research institution under the Uganda National Health Research Organization. The Institute was founded in 1936 by the Rockefeller Foundation as a Yellow Fever Research Institute. Presently, UVRI is owned and operated by the Government of the Republic of Uganda with a mandate to carry out research on communicable diseases affecting humanity, with continued emphasis on viral infections. The institution houses specialized laboratories for Arboviruses and Filoviruses in Sub-Saharan Africa, and is best known for the discovery of Zika virus, West Nile virus, Chikungunya virus, Bwamba virus, Semliki forest virus, O'nyong'nyong and Kadam viruses. UVRI was also an early pioneer in HIV/AIDS research and continues groundbreaking work in that field.



The UVRI campus in Entebbe hosts several long-term partner organizations, including the CDC, the United Kingdom Medical Research Council, and other non-governmental partners. The facility is home to international, national and regional reference laboratories such as the reference laboratory for HIV (HRL lab), the zoonotic laboratory and a highly specialized biosafety level three (BSL-3) laboratory for Viral Hemorrhagic Fevers (VHF), the high consequence pathogens Medical Research Council Unit, and the EPI/vaccine preventable diseases laboratory which serves as the national center for research and epidemiological investigations of vaccine preventable disease in Uganda and the horn of Africa. The US government, through CDC, DoD, and NIH, has played a critical role in the establishment of many of these laboratories as well as the biosecurity systems in use. The quality of the laboratories and capacity of UVRI are such that the institute also serves as an international reference laboratory, receiving and processing samples from neighboring countries in the region.

10:00 am–12:00 pm

**Tour of UVRI campus led by Professor Pontiano Kaleebu, including the following laboratories:**

- Arbovirology laboratories
- Viral hemorrhagic fever laboratories
- Expanded Program on Immunization laboratories
- HIV Reference laboratories
- Uganda Medical Informatics Centre
- Medical Research Council (MRC)/UVRI & London School of Hygiene and Tropical Medicine (LSHTM) virology and immunology laboratories

12:00–1:00 pm

**Lunch hosted by UVRI**

1:00–2:30 pm

**Meetings with UVRI-IAVI program staff:**

**1:00–1:10:** General overview of UVRI-IAVI program; **Brenda Okech**, Director  
**Introductions and presentations from department heads:**

**1:10–1:30: Clinical programs overview; Annet Nanvubya, Clinical Trials Manager**

**1:30–1:40: Research Pharmacy overview; Umar Nkuutu, Pharmacist**

**1:40–1:50: Site Laboratory overview; Enoch Muyanja, Laboratory Manager**

**1:50–2:00: Data Management overview; Teddy Nakawesa, Data Manager**

**2:00–2:20: Community programs overview; Gertrude Nanyonjo, Acting Head of Community Studies**

**1:50–2:00: Quality Management overview; David Mugisha, Quality Coordinator**

2:30–3:00 pm

**Presentation on HIV Prevention Trial Network (HPTN) 084 LIFE trial (Long-acting Injectable For the Epidemic), a Phase 3 Double Blind Safety and Efficacy Study, by Juliet Mpendo, Medical Director & Principal Investigator. Participants will learn about the study design, protocol, ongoing follow-up and potential impact**

of this important Phase III clinical trial. HPTN 084 is a study being done to evaluate the safety and efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis (PrEP) in HIV-Uninfected Women.

PrEP agents are needed that do not depend on daily or near-daily pill-taking. The study is the first large-scale clinical trial of a long-acting injectable medication for HIV prevention in sexually active women. If found to be safe and effective for HIV pre-exposure prophylaxis (PrEP), injectable CAB may be an easier, more desirable, discreet alternative to daily oral TDF/FTC for some women. The development of alternative agents for PrEP, and/or more adherence-friendly schedules for currently available agents, could increase prevention choices and increase acceptability. Long-acting injectable agents have the potential to prevent HIV acquisition without relying on adherence to a daily oral regimen.

3:00–3:10 pm

Tea break; time for group discussion

3:10–4:10 pm

In-depth discussion of community activities and meeting with Community Advisory Board (CAB) members to discuss the impacts of this research, challenges, and presentation of how CAB members ensure buy-in of community leaders and members and prevent myths and mitigate concerns about research within the community.  
Open Q&A with CAB

4:10–4:40 pm

Discussion with Community Liaison Officers (CLOs). Briefing on structural barriers to accessing healthcare in the Lake Victoria fishing community and overview of what the group will see Thursday. Open dialogue with CLOs about their community outreach work, including challenges, how they became involved, and future directions of biomedical research in the region.

4:40–5:10 pm

Tour of UVRI Clinic and discussions with **Dr. Mpendo** and team conducting HPTN 084 study. Participants will gain an understanding of what a typical clinic visit is entails for trial participants, learn about the process of enrolling participants (informed consent forms, screenings), see where biomedical samples are collected and the process of analyzing them to determine the trial outcomes.

5:10–5:30pm

Transit to dinner

5:30–7:00 pm

Working dinner – debrief of the day and review of next day's itinerary  
*Location: Goretti's Pizzeria*

**Overnight: Protea Hotel Entebbe**

### Day 4 – Thursday, August 22

**Location:** Lake Victoria fishing islands

**Attire: Casual (dress to be in direct sun much of the day)**

7:30–8:30 am

**Breakfast and daily briefing reviewing daily itinerary and introducing points for discussion during site visits**

**Location:** Protea Hotel Entebbe

8:30–9:00 am

### Transit to boat launch site

9:00–10:30 am

### Boat transfer to Kimi Island

**Led by Gertrude Nanyonjo and Mathias Wambuzi**

10:30 am-12:00 pm

## Overview of clinical programs on Kimi Island and Q&A with local CAB.

Participants will gain an understanding of the research efforts Uganda fishing communities are participating in, structural barriers fisherfolk face in accessing healthcare, and their increased occupational and environment risk for acquiring HIV. A recent study of fisherfolk in Uganda found that 22% were HIV positive, rates being higher among women than men. Risk factors associated with the elevated vulnerability of fisherfolk to HIV infection include being mostly youth or young adults, being mobile, being involved in risky forms of work, being relatively poor and marginalized, being inclined towards alcohol use, and being less able to readily access health services.

12:00–12:30 pm

### Boat transfer to Nsadzi Island

12:30–1:30 pm

**Lunch (provided by community)**

1:30–4:00 pm

Tour of island clinic and ongoing work. Participants will visit another fishing community and see the local clinic that serves these regional islands. They will hear more about the current ongoing research as well as the integrated HIV treatment and care at the health clinic. This site will highlight the important link between research efforts toward new HIV prevention tools and implementation of current tools (through programs like PEPFAR) and how their collaboration increases access to HIV services for a population that would otherwise have limited access to healthcare.

4:00–5:15 pm

### Transit to landing site

**5:15–5:45 pm**

Transit to hotel, time to change



5:45–6:15 pm

Transit to dinner

6:15–7:45 pm

Working dinner – debrief of the day and review of next day's itinerary  
*Location:* Protea Hotel Entebbe

Overnight: Protea Hotel Entebbe

## Day 5 – Friday, August 23

*Location:* Entebbe

*Attire:* Casual

8:00–9:00 am

Breakfast and daily briefing reviewing daily itinerary and introducing points for discussion during site visits

9:00–9:30 am

Transit to Zika Forest UVRI research facility

9:30–10:30 am

Tour Zika Forest UVRI research facility tour; overview of UVRI activities. Zika Forest has served as a protected field research station of UVRI since UVRI was established in Entebbe, Uganda in 1936. The 25-acre forest has rich bio-diversity and is home to over 40 types of mosquitoes. It serves as a critical venue for innovative scientific research, offering a platform for surveillance and field studies of emerging and re-emerging infectious diseases. Investigations of mosquitos at Zika Forest started in 1946 as part of the study of human yellow fever. In 1947 researchers at UVRI isolated the RNA of a flavivirus, which was named the Zika Virus. Today, Zika and related Arboviruses such as Yellow Fever, Dengue, West Nile and Japanese Encephalitis pose critical health security threats around the world and have spread outside their geographic areas from Micronesia to the United States.

At Zika Forest, the delegation will hear from UVRI leadership on the history of Zika Forest and its impact on global health, citing various research and surveillance activities, key discoveries made, and on-going projects related to Arboviruses such as Yellow Fever, Dengue, West Nile and Zika virus. The delegation will see the observation and baiting tower and will hear about past Yellow Fever research using trapped monkeys. These efforts led to the elucidation of the Yellow Fever virus cycle, along with other research on the ecology of mosquito vectors for arboviruses. The visit will help to emphasize key findings and the global relevance of this research, connections between research conducted at Zika Forest and UVRI, and the impact of the work supported by the US President's Malaria Initiative (PMI) in Uganda.  
*Location:* Zika Forest UVRI research facility

10:30–11:00 am	Transit to Kasenye landing site clinic
11:00–12:00 pm	Tour the Kasenye landing site clinic, an HPTN 084 satellite clinic on the shores of Lake Victoria. Participants will tour the facility on an active clinic day to learn about how clinic trial participants are enrolled in the study and witness the operations of a small, local health facility.
12:00–12:30 pm	Tour of landing site led by local political leader (the equivalent of a city council member). He will walk us through the community and highlight aspects of the fishing industry which contribute to an increased risk of acquiring HIV. Participants will gain an understanding of how lifestyles differ slightly from the island based fishing communities and how access to healthcare and general health outcomes differ.
12:30–1:00pm	Transit to UVRI
1:00–2:30 pm	Moderated lunch discussion with early-career investigators at UVRI and Professor Pontiano Kaleebu, Director of UVRI. Discussion of research context in Uganda and motivations to pursue careers in global health research.
2:30–5:00 pm	Break / time to pack
5:00–7:00 pm	Final working dinner and debrief conversation covering impressions from the trip and site visits, as well as time to ask questions and give feedback. <i>Location:</i> hotel restaurant
7:00–8:00 pm	Break / check out of hotel
8:00 pm	Transit to Entebbe airport
11:20 pm	Depart for Dulles on United Airlines (via Brussels)
<b>Transit Day – Saturday, August 24</b>	
2:20 pm	Arrive at Dulles

**EMPLOYEE PRE-TRAVEL AUTHORIZATION**

**Pre-Travel Filing Instructions:** Complete and submit this form at least 30 days prior to the travel departure date to the **Select Committee on Ethics in SH-220**. Incomplete and late travel submissions will not be considered or approved. This form must be typed and is available as a fillable PDF on the Committee's website at [ethics.senate.gov](http://ethics.senate.gov). Retain a copy of your entire pre-travel submission for your required post-travel disclosure.

Name of Traveler: Jacob VanceEmploying Office/Committee: Sen. MoranPrivate Sponsor(s) (list all): PATH/Global Health Technologies Coalition, International AIDS Vaccine InitiativeTravel date(s): August 17-24, 2019

*Note: If you plan to extend the trip for any reason you must notify the Committee.*

Destination(s): Kampala & Entebbe, Uganda

Explain how this trip is specifically connected to the traveler's official or representational duties:

As Legislative Correspondent assigned to the health portfolio, this trip will be a resource to better understand how investments in NIH, CDC, USAID, and DoD advance R&D for new tools including drugs, vaccines, and diagnostics for long-standing global health challenges and emerging infectious diseases.

Name of accompanying family member (if any): \_\_\_\_\_

Relationship to Employee: ☐ Spouse ☐ Child

I certify that the information contained in this form is true, complete and correct to the best of my knowledge:

7/15/2019  
(Date)

Jacob C. Vance  
(Signature of Employee)

TO BE COMPLETED BY SUPERVISING SENATOR/OFFICER (President of the Senate, Secretary of the Senate, Sergeant at Arms, Secretary for the Majority, Secretary for the Minority, and Chaplain):

I, Sen. Moran hereby authorize Jacob Vance  
(Print Senator's/Officer's Name) (Print Traveler's Name)

an employee under my direct supervision, to accept payment or reimbursement for necessary transportation, lodging, and related expenses for travel to the event described above. I have determined that this travel is in connection with his or her duties as a Senate employee or an officeholder, and will not create the appearance that he or she is using public office for private gain.

I have also determined that the attendance of the employee's spouse or child is appropriate to assist in the representation of the Senate. (signify "yes" by checking box) ☐

7/15/2019  
(Date)

Jerry Moran  
(Signature of Supervising Senator/Officer)